AR123085A1 - ANTI-INTEGRIN b7 ANTIBODY FORMULATIONS AND DEVICES - Google Patents
ANTI-INTEGRIN b7 ANTIBODY FORMULATIONS AND DEVICESInfo
- Publication number
- AR123085A1 AR123085A1 ARP210102115A ARP210102115A AR123085A1 AR 123085 A1 AR123085 A1 AR 123085A1 AR P210102115 A ARP210102115 A AR P210102115A AR P210102115 A ARP210102115 A AR P210102115A AR 123085 A1 AR123085 A1 AR 123085A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- seq
- integrin
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se proporcionan formulaciones que comprenden un anticuerpo anti-integrina b7 o un fragmento de unión a antígeno del mismo, que incluyen formulaciones farmacéuticas. También se proporcionan artículos de fabricación que comprenden dichas formulaciones y métodos para usar dichas formulaciones. Reivindicación 1: Una formulación que comprende un anticuerpo monoclonal anti-integrina b7, en la que la concentración del anticuerpo anti-integrina b7 es al menos aproximadamente 100 mg/ml, la viscosidad de la formulación es menor que aproximadamente 20 centipoises (cP) a 25ºC y en la que la formulación tiene estabilidad extendida. Reivindicación 30: Una formulación que comprende un anticuerpo anti-integrina b7, en tampón histidina 20 mM o en tampón histidina aproximadamente 20 mM, pH 5,8 o pH entre 5,7 y 5,9 o pH entre 5,75 y 5,85, polisorbato 20 al 0,04% o polisorbato 20 aproximadamente al 0,04% y succinato de arginina 200 mM o succinato de arginina aproximadamente 200 mM, en la que la concentración del anticuerpo anti-integrina b7 es 150 mg/ml o aproximadamente 150 mg/ml, y en la que el anticuerpo anti-integrina b7 comprende tres regiones hipervariables (HVR) de la cadena ligera, HVR-L1, HVR-L2 y HVR-L3, y tres HVR de la cadena pesada, HVR-H1, HVR-H2 y HVR-H3, en las que: (i) la HVR-L1 comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 1; (ii) la HVR-L2 comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 2; (iii) la HVR-L3 comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 3; (iv) la HVR-H1 comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 4; (v) la HVR-H2 comprende la secuencia de aminoácidos SEQ ID Nº 5; y (vi) la HVR-H3 comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 6 o SEQ ID Nº 7.Formulations comprising an anti-β7 integrin antibody or an antigen-binding fragment thereof are provided, including pharmaceutical formulations. Articles of manufacture comprising said formulations and methods of using said formulations are also provided. Claim 1: A formulation comprising an anti-β7 integrin monoclonal antibody, wherein the concentration of the anti-β7 integrin antibody is at least about 100 mg/mL, the viscosity of the formulation is less than about 20 centipoise (cP) at 25°C and wherein the formulation has extended stability. Claim 30: A formulation comprising an anti-integrin b7 antibody, in 20 mM histidine buffer or in approximately 20 mM histidine buffer, pH 5.8 or pH between 5.7 and 5.9 or pH between 5.75 and 5, 85, 0.04% polysorbate 20 or about 0.04% polysorbate 20 and 200 mM arginine succinate or about 200 mM arginine succinate, wherein the concentration of the anti-integrin b7 antibody is 150 mg/ml or about 150 mg/ml, and wherein the anti-β7 integrin antibody comprises three light chain hypervariable regions (HVRs), HVR-L1, HVR-L2, and HVR-L3, and three heavy chain HVRs, HVR-H1 , HVR-H2 and HVR-H3, wherein: (i) the HVR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 1; (ii) the HVR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 2; (iii) the HVR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 3; (iv) HVR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 4; (v) the HVR-H2 comprises the amino acid sequence SEQ ID NO: 5; and (vi) the HVR-H3 comprises the amino acid sequence set forth in SEQ ID No. 6 or SEQ ID No. 7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063059427P | 2020-07-31 | 2020-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123085A1 true AR123085A1 (en) | 2022-10-26 |
Family
ID=77693570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102115A AR123085A1 (en) | 2020-07-31 | 2021-07-29 | ANTI-INTEGRIN b7 ANTIBODY FORMULATIONS AND DEVICES |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4188958A1 (en) |
JP (1) | JP2023536158A (en) |
KR (1) | KR20230041071A (en) |
AR (1) | AR123085A1 (en) |
AU (1) | AU2021316017A1 (en) |
BR (1) | BR112023001734A2 (en) |
CA (1) | CA3190109A1 (en) |
IL (1) | IL300133A (en) |
MX (1) | MX2023001157A (en) |
TW (1) | TW202222832A (en) |
WO (1) | WO2022026699A1 (en) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
ES2304786T3 (en) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
RS57636B1 (en) | 2004-09-03 | 2018-11-30 | Genentech Inc | Humanized anti-beta7 antagonists and uses therefor |
JP6219556B2 (en) | 2008-05-16 | 2017-10-25 | ジェネンテック, インコーポレイテッド | Use of biomarkers for evaluation of treatment of gastrointestinal inflammatory disorders using beta7 integrin antagonists |
EP2403874A1 (en) | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
MX367097B (en) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULATION FOR ANTI-a4ß7 ANTIBODY. |
JP5814465B2 (en) | 2011-06-17 | 2015-11-17 | エス・ホー・エル・グループ・アクチボラゲットShl Group Ab | Injection device |
BR112013032570B1 (en) | 2011-06-17 | 2021-02-23 | Shl Medical Ag | injection device |
RU2015145610A (en) | 2013-03-27 | 2017-05-04 | Дженентек, Инк. | APPLICATION OF BIOMARKERS FOR THE EVALUATION OF TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS BY BETA7 INTEGRIN ANTAGONISTS |
MX2016012282A (en) | 2014-03-27 | 2017-01-06 | Genentech Inc | Methods for diagnosing and treating inflammatory bowel disease. |
AU2016222683A1 (en) * | 2015-02-26 | 2017-07-13 | Genentech, Inc. | Integrin beta7 antagonists and methods of treating crohn's disease |
EP3810085A1 (en) * | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
-
2021
- 2021-07-29 IL IL300133A patent/IL300133A/en unknown
- 2021-07-29 EP EP21766732.8A patent/EP4188958A1/en not_active Withdrawn
- 2021-07-29 JP JP2023506189A patent/JP2023536158A/en active Pending
- 2021-07-29 TW TW110127937A patent/TW202222832A/en unknown
- 2021-07-29 AU AU2021316017A patent/AU2021316017A1/en active Pending
- 2021-07-29 AR ARP210102115A patent/AR123085A1/en unknown
- 2021-07-29 CA CA3190109A patent/CA3190109A1/en active Pending
- 2021-07-29 BR BR112023001734A patent/BR112023001734A2/en unknown
- 2021-07-29 WO PCT/US2021/043690 patent/WO2022026699A1/en active Application Filing
- 2021-07-29 MX MX2023001157A patent/MX2023001157A/en unknown
- 2021-07-29 KR KR1020237006223A patent/KR20230041071A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022026699A1 (en) | 2022-02-03 |
CA3190109A1 (en) | 2022-02-03 |
IL300133A (en) | 2023-03-01 |
TW202222832A (en) | 2022-06-16 |
AU2021316017A1 (en) | 2023-02-16 |
BR112023001734A2 (en) | 2023-02-28 |
EP4188958A1 (en) | 2023-06-07 |
KR20230041071A (en) | 2023-03-23 |
JP2023536158A (en) | 2023-08-23 |
MX2023001157A (en) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR088579A1 (en) | FORMULATIONS OF ANTIBODIES | |
CO6331344A2 (en) | ISOLATED ANTIBODIES THAT JOIN VEGF, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND A PHARMACEUTICALLY ACCEPTABLE CARRIER AND USES OF THE SAME | |
JP2020518600A5 (en) | ||
PE20121023A1 (en) | ANTIBODIES AND IMMUNOCONJUGATES | |
AR127344A2 (en) | ANTIBODY-DRUG CONJUGATES COMPRISING STING AGONISTS | |
AR091462A1 (en) | ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE | |
PE20201503A1 (en) | STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS | |
AR091701A1 (en) | ANTI-CD22 ANTIBODIES AND IMMUNOCATE PLAYERS | |
AR095451A1 (en) | FORMULATION OF ANTIBODIES | |
AR109298A1 (en) | MULTIEPITOPIC AND MULTIVALENT ANTIBODIES THAT HAVE AGONIST ACTIVITY AND METHODS OF USE | |
PE20120341A1 (en) | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION | |
JP2017514461A5 (en) | ||
AR092216A1 (en) | STABLE FORMULATIONS OF ANTIBODIES AGAINST TSLP | |
JP2020518598A5 (en) | ||
NZ601125A (en) | Antibody formulation and therapeutic regimens | |
PE20121579A1 (en) | BINDING PROTEINS TO THE HUMAN IL-23 ANTIGEN | |
ES2628108T3 (en) | Multispecific Antibodies | |
CO6220835A2 (en) | ANTI-ROBO4 ANTIBODIES AND THEIR USES | |
AR099855A1 (en) | ANTIINFLUENZA B VIRUS HEMAGLUTININE ANTIBODIES AND METHODS OF USE | |
AR115365A1 (en) | HUMAN ANTI-PD-L1 ANTIBODY FORMULATIONS | |
AR102593A1 (en) | ANTI-PDGF-B ANTIBODIES AND METHODS OF USE | |
PE20140195A1 (en) | ANTIBODY COMPOSITIONS AND METHODS OF USE | |
CO2022013885A2 (en) | bispecific antibody | |
JP2020158505A5 (en) | ||
NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |